Drug Trial Radar · NCT03886688
HEC53856 Phase 1 Study - Single and Multiple Oral Dosing in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Apr 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
116
Actual
Start
May 14, 2019
Primary completion
Jan 1, 2020
Study completion Jan 1, 2020
Sponsor
- Lead sponsor
- Sunshine Lake Pharma Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 22, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To evaluate the safety, tolerability and pharmacokinetics of HEC53856 after single or multiple oral administration, as well as the food effect on the pharmacokinetics, in healthy non-elderly subjects.
Conditions
- Healthy
Interventions
HEC53856Drug
oral administration
placeboDrug
oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse Events [Safety and Tolerability]Time frame: Up to Day 10 after last dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
First Hospital of Jilin University
Changchun, Jilin, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.